The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Highlights,The FDA has removed Eli Lilly’s popular weight-loss and diabetes drugs from its shortage list, reducing the market ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’ ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...